ICPV Study Days
See below for details of our latest study day. Reports from this event will be available soon.
Papers and reports from previous study days can be found on the left.
Cutting-Edge Cancer Treatments
Expense and Expectation?
ICPV Workshop, Thursday 23rd February 2012
Cancer Research UK, London Research Institute,
44 Lincoln’s Inn Fields, WC2A 3LY
Aim of the workshop – For delegates to understand the cost/benefits of new (and existing) technologies and treatments for cancer patients the public expectations of the NHS in providing cancer treatments and the importance of PPI in cancer research and services.
Impact of the workshop –For delegates to apply in their PPI work,an informed patient perspective on the costs/benefits of new (and existing) technologies and treatments for cancer patients in the current economic climate.
Provisional Programme
Introduction and clarification of aims of the workshop
Richard Stephens, Incoming Chair of CLG & ICPV Member
What do cancer patients want from the NHS?
Laura Thomas, Ipsos MORI
Stratified medicine – What is it and could it reduce costs in long term?
Dr Emily Shaw, Clinical Lead, Stratified Medicine Unit, Cancer Research UK
What is the role of chemoprevention & do we need to licence drugs for this use? What is the future for use of orphan drugs?
Professor Jack Cuzick, Wolfson Institute
Imaging in research and early drug development – role of ECMC What happened to the “Star Wand?”
Prof Kerry Chester UCL (TBC)
Delivering World Class Radiotherapy
Tim Cooper, Associate Director-Radiotherapy, National Cancer Action Team
New models of radiotherapy
Dr Jayant Vaidya, Breast Cancer Specialist, University College London
How do we achieve cost effective cancer treatments in the UK?
Prof Peter Littlejohns Kings College London & previously at NICE
View from Industry (details of talk TBC)
Rob Day, Head of Oncololgy, Pfizer
Stuart Pritchard, GSK
To contact us about this event or any future meeting please email or use our online contact form
Print